Pharmacokinetics of antivirals in neonate

Early Human Development

Volumn 81, Issue 9, 2005, Pages 773-780

  Pacifici, Gian Maria ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Acyclovir; Antivirals; Didanosine; Ganciclovir; Lamivudine; Nelfinavir; Neonate; Nevirapine; Pharmacokinetics; Pleconaril; Stavudine; Zidovudine

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; DIDANOSINE; GANCICLOVIR; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PLECONARIL; STAVUDINE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MEGADOSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; NEWBORN; PERINATAL PERIOD; PREMATURITY; REVIEW;

ANTIVIRAL AGENTS; HUMANS; INFANT, NEWBORN; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 24344446983     PISSN: 03783782     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2005.06.001     Document Type: Review

References (37)

1. UNAIDS 2004 report on the global AIDS epidemic [online]. Available from URL: http://www.unaids.org/bangkok2004/report.html.
2. P. Duff HIV infection in women Prim Care Update Ob Gyns 3 1996 45 49
3. G.C. John, and J. Kreiss Mother-to-child transmission of HIV Epidemiol Rev 18 1996 149 157
4. Y. Bryson Perinatal HIV-1 transmission: recent advances and therapeutic interventions AIDS 10 1996 S33 S42
5. E.M. Connor, R.S. Sperling, R. Gelber, R. Kiselev, M. Bey, and W. Shearer Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment N Engl J Med 331 1994 1173 1180
6. G.M. Pacifici Transfer of antivirals across human placenta Early Human Dev 81 2005 647 654
7. M. Mirochnick, E. Capparelli, and J. Connor Pharmacokinetics of zidovudine in infants: a population analysis across studies Clin Pharmacol Ther 66 1999 16 24
8. M. Mirochnick, E. Cappelli, W. Danker, R.S. Sperling, R. van Dyke, and S.A. Spector Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus Antimicrob Agents Chemother 42 1998 808 812
9. D. Moodley, K. Pillay, K. Naidoo, J. Moodley, M.A. Johnson, and K.H.P. Moore Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours J Clin Pharmacol 41 2001 732 741
10. F.D. Boucher, J.F. Modlen, S. Weller, A. Ruff, M. Mirochnick, and S. Pelton Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus Pediatr Pharmacol Ther 122 1993 137 144
11. G.M. Pacifici, L. Evangelisti, and L. Giuliani Zidovudine glucuronosyl transferase in human liver: interindividual variability Int J Clin Pharmacol Ther 34 1996 329 334
12. M.R. Blum, S.H.T. Liao, and P. Ge Miranda Pharmacokinetics and bioavailability of zidovudine in humans Am J Mes 85 Suppl. 2A 1988 189 294
13. K.E. Thummel, and D.D. Shen Design optimiation of dosage regimen: pharmacokinetic data J.G. Hardmand L.E. Limbrid A. Goodman Gilman The Pharmacological Basis of Therapeutics 2001 McGraw-Hill Net Work 1917 2023
14. Y. Wang, E. Livingstone, S. Patil, R. McKinney, A.D. Bardegurz, and J. Gandia Pharmacokinetics of Didanosine in antepartum human immunodeficiency virus-infected pregnant women and their neonates: an AIDS clinical trials group study J Infect Dis 180 1999 153
15. C. Rongkavilit, P. Thaithumyanon, T. Chuenyam, B.D. Damle, S. Limpongsanurak, and C. Boonrod Pharmacokinetics of stavudine and didanosine coadministered with Nelfinavir in human immunodeficiency virus-exposed neonates Antimicrob Agents Chemother 45 2001 3585 3590
16. J. Moodley, D. Moodley, K. Pillay, Coovadia, J. Saba, and R. van Leeuwen Pharmacokinetics and antiretroviral of lamivudine alone and coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring J Infect Dis 178 1998 1327 1333
17. C. Rongkavilit, R.P. van Heeswijk, S. Limpongsanurak, P. Thaithumyanon, C. Boonrod, and E.A. Hassink Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates J Acquir Immune Defic Syndr 29 5 2002 455 463
18. V.B. Pai, and M.C. Nahata Nelfinavir mesylate: a protease inhibitor Ann Pharmacother 33 1999 325 339
19. D. Ratanasavnh, P. Beaume, F. Morel, J.F. Flinois, F.P. Guengerich, and A. Guilluzo Intralobular distribution and quantitation of cytochrome P-450 enzymes in human liver as a function of age Hepatology 13 1991 1142 1151
20. E.V. Capparelli, J.L. Sullivn, L. Mofenson, E. Smith, B. Graham, and P. Britto Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants Pediatr Infect Dis J 20 2001 746 751
21. M. Mirochinick, T. Fenton, P. Gagner, J. Pav, M. Gwynne, and S. Siminski Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates J Infect Dis 178 1998 368 374
22. R.L. Murphy, and J.L. Montaner Nevirapine: a review of its development, pharmacological profile, and potential for clinical use Opin Investig Drugs 5 1996 1183 1199
23. D. Kimberlin, D. Powell, W. Gruber, P. Diaz, A. Arvin, and M. Kumar Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to skin, eyes and mouth: results of a phase I/II trial Pediatr Infect Dis J 15 1996 247 254
24. D. Kimberlin Herpes simplex virus, meningitis and encephalitis in neonates Herpes 11 Suppl. 2 2004 65A 76A
25. W.M. Sullender, A.M. Arvin, P.S. Diaz, J.D. Connor, R. Straube, and W. Danker Pharmacokinetics of acyclovir in suspension in infants and children Antimicrob Agents Chemother 31 1987 1722 1726
26. E.C. Mar, Y.C. Cheng, and E.S. Huang Effect of 9-(1,3-dihydroxy-2- propoxymethyl)guanine on human cytomegalovirus replication in vitro Antimicrob Agents Chemother 24 1983 518 521
27. M.J. Tocci, T.J. Livelli, H.C. Perry, C.S. Crumpacker, and A.K. Field Effects of the nucleoside analog 2′-nor-2′-deoxyguanosine on human cytomegalovirus replication Antimicrob Agents Chemother 25 1984 247 252
28. J.M. Trang, L. Kidd, W. Gruber, G. Storch, G. Demmler, and R. Jacobs Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infection Clin Pharmacol Ther 53 1993 15 21
29. X.-J. Zhou, W. Gruber, G. Demmler, R. Jacobs, P. Reuman, and S. Adler Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infection Antimicrob Agents Chemother 40 1996 2202 2205
30. A.D. Webster Plecoranil an advance in the treatment of enteroviral infection in immuno-compromised patients J Clin Virol 32 2005 1 6
31. A.R. Tunkel Double-blind placebo-controlled trial of peconaril in infants with enteroviral meningitis Curr Infect Dis Rep 6 2004 295 296
32. B. Jubelt Pleconaril for infantile enterovirus meningitis Curr Neurol Neurosci Rep 3 22 2003 459 460
33. G.L. Kearns, J.S. Bradley, R.F. Jacobs, E.V. Capparelli, L.P. James, and K.M. Johnson Single dose pharmacokinetics of pleconaril in neonates Pediatr Infect Dis J 19 2000 833 839
34. S.M. Abdel-Rahman, and G.L. Kerns Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution and effect of food Antimicrob Agents Chemother 42 1998 2706 2709
35. A. Viani, G. Rizzo, M. Carrai, and G.M. Pacifici Interindividual variability in the concentrations of albumin and alpha-1-acid glycoprotein in patients with renal or liver disease, newborns and healthy subjects: implications for binding of drugs Int J Clin Pharmacol Ther Toxicol 30 1992 128 133
36. G.M. Pacifici, A. Viani, and G. Taddeucci-Brunelli Serum protein binding of furosemide in newborn infants and children Dev Pharmacol Ther 10 1987 13 21
37. G.M. Pacifici, A. Viani, G. Taddeucci-Brunelli, G. Rizzo, M. Carrai, and H.U. Schulz Effects of development, aging, and renal and hepatic insufficiency as well as hemodialysis on the plasma concentrations of albumin and alpha 1-acid glycoprotein: implications for binding of drugs Ther Drug Monit 8 1986 259 263